EASTGATE BIOTECH CORP

As of September 30, 2017, EASTGATE BIOTECH CORP carries a market capitalization of 1.25M, placing it among publicly traded companies globally. Its enterprise value stands at 4.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2017, EASTGATE BIOTECH CORP has 1.14B shares outstanding.

These figures are as of September 30, 2017. The price-to-sales ratio is 14.42, and the price-to-book ratio stands at -0.24.

These figures are as of September 30, 2017. The EV/Sales ratio of 98.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.32M versus a market cap of 1.25M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2017, EASTGATE BIOTECH CORP maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -58.19, indicating conservative leverage, while an interest coverage ratio of -12.72 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2017. Return on assets (ROA) is negative at -391.47, reflecting losses generated across the asset base. The company generates approximately 14,704.33 in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on October 12, 2026, EASTGATE BIOTECH CORP's stock has gained approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended September 30, 2017, EASTGATE BIOTECH CORP generated 44,113.00 in revenue and converted that into -4.23M in net income, yielding earnings per share of -0.01. EBITDA reached -3.79M, while operating income came in at -3.82M.

As of September 30, 2017, EASTGATE BIOTECH CORP holds 4,911.00 in cash and equivalents against 3.08M in total debt, resulting in a net debt position of 2.70M. Total book value stands at -5.29M, with working capital of -6.79M providing operational flexibility.

EASTGATE BIOTECH CORP produced -1.75M in operating cash flow over the twelve months ended September 30, 2017.

Over the twelve months ended September 30, 2017, EASTGATE BIOTECH CORP posted a gross margin of -206.74, reflecting its pricing power and cost economics. The operating margin of -8,649.62 and net profit margin of -9,598.82 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2017. Free cash flow yield is negative at -275.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -139.83, meaning EASTGATE BIOTECH CORP raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2017, EASTGATE BIOTECH CORP has an Altman Z-Score of -27.71, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.